Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Novartis Takes Cardiovascular Setbacks In Stride After Poor Showing At ACC

Executive Summary

Novartis' strategy to expand its cardiovascular and metabolics business in advance of the patent expiry of its blockbuster Diovan included running a lot of clinical trials to add indications and amass outcomes data. But studies designed to expand use also have the potential to disappoint, as was the case for several trials presented at the American College of Cardiology annual meeting

You may also be interested in...

Novartis And Daiichi Sankyo Obtain Japanese Price Listings, May Set Precedent For Combination Re-pricing

Japan's Central Social Medical Insurance Agency, also called Chuikyo, recently approved price listings for Novartis' and Daiichi Sankyo's respective potential blockbuster combination diabetes drugs, and the council also agreed to review drug pricing policy to encourage investment in drug innovation

Failed Post-MI Trial Foils Novartis' Higher ASPIRE-ations For Tekturna

ACC panelist: Study was not powered for outcomes, but doubling in death rates is still "very disturbing."

Abbott's Fibrate Franchise Will Likely Remain Limited To High-Risk Patients After ACCORD

Report from ACC: Experts advise reading the fine print of the study - which failed to show an overall outcome benefit - as sub-group analysis shows highest-risk patients might benefit.

Related Content


Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts